#USA #San Francisco #AusperBio #Hepatitis B #AHA-137

AusperBio's AHB-137: A New Hope for Chronic Hepatitis B

A groundbreaking development has emerged from AusperBio Therapeutics, a biotechnology firm dedicated to innovating treatments for chronic hepatitis B (CHB). The company recently revealed compelling results from its Phase IIa clinical trial of AHB-137, a lead investigational therapy targeting this stubborn viral infection.

These results were shared at the HEP-DART 2025 conference, where experts gathered to discuss advancements in liver diseases. The study aims to evaluate AHB-137's efficacy when administered as a monotherapy to patients already receiving stable nucleos(t)ide analogue (NA) therapy.

Significant Findings

The most striking outcome was a 30% functional cure rate observed at Week 72 for patients with baseline HBsAg levels between 100 to 1,000 IU/mL. This figure exemplifies a milestone in hepatitis B treatment, as achieving a functional cure had been considered an elusive goal till now. Moreover, some patients with baseline HBsAg levels between 100 to 3,000 IU/mL exhibited functional cure rates of 13% and 19% for the lower (225 mg) and higher (300 mg) dosing cohorts, respectively. Based on the data, the 300 mg dosage has been selected for further studies, indicating its potential effectiveness.

Sustained Off-Treatment Effects

An impressive aspect of the AHB-137 trial results was the durability of treatment effects. Following treatment, 100% of the participants remained HBV DNA-negative for a full 24 weeks. Furthermore, sustained suppression of HBsAg was demonstrated, with 89% and 82% of patients maintaining complete responses at Week 72 for the respective baseline HBsAg levels—again showcasing AHB-137's long-lasting antiviral effects.

Safety Profile

Safety is paramount in any healthcare breakthrough, and AHB-137 has shown favorable safety and tolerability throughout the trial. There were no severe adverse effects directly linked to the drug, and most side effects encountered were mild or moderate during the treatment phase.

Professor Niu Junqi, the principal investigator and a leading hepatologist at The First Hospital of Jilin University, highlighted the historic nature of these findings. He noted that a functional cure rate of 30% is a key indicator of potential treatment improvement, especially in a disease that has proven difficult to eradicate. The study's outcomes herald a shift in how chronic hepatitis B may be treated moving forward, potentially alleviating the burden of lifelong therapy.

Future Directions

The excitement surrounding AHB-137 is palpable. Dr. Guofeng Cheng, AusperBio's CEO, expressed pride in the results presented at such a prestigious gathering, underscoring the need for innovative antiviral approaches. As they work on advancing pivotal clinical programs aimed at new hepatitis B treatments, the company seeks to redefine therapeutic goals from mere control to achieving functional cures.

The Road Ahead

AHB-137 represents more than just a novel therapy; it embodies hope for the millions affected by chronic hepatitis B worldwide. Multi-faceted in action, this drug is designed to target the virus on several fronts, primarily suppressing HBsAg, inhibiting viral replication, and reactivating immune responses. With further trials planned, including Phase III studies in China and additional Phase II assessments in multiple centers, the medical community keenly observes AusperBio's movements in the upcoming months.

The clinical promise of AHB-137 could transform the narrative for chronic hepatitis B treatment, shifting the focus toward developing effective curative therapies rather than managing symptoms over a lifetime.